Eli Lilly and Co said on Thursday its new two-in-one diabetes drug was successful in lowering blood sugar and reducing weight, sending its shares to a record high and weighing on those of arch-rival Novo Nordisk .
Source:: Reuters – Business News
Newswire
- [ April 23, 2025 ] Snow Lake (NASDAQ: LITM) Phase 2 Drill Uranium Program Underway at Engo Valley Newsmakers
- [ April 23, 2025 ] Ensysce Biosciences (NASDAQ:ENSC) Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder Newsmakers
- [ April 15, 2025 ] Rezolve Ai (NASDAQ: RZLV) Secures $9.8 Million Annual Contract with Liverpool Mexico Newsmakers
- [ April 15, 2025 ] Skye Bioscience (NASDAQ: SKYE) Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model Newsmakers
- [ April 14, 2025 ] ARB IOT Group (NASDAQ: ARBB)Secures Approximately USD53.0 Million Order for Supplying AI Servers Newsmakers
- [ April 10, 2025 ] Canadian Securities Exchange Mark Faulkner FRAUD and CORRUPTION Exposed! CSE = Canada SCAM Exchange? Investigation
- [ April 9, 2025 ] Microbot Medical® Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY® Endovascular Robotic System Healthcare
- [ April 9, 2025 ] SUNation Energy (NASDAQ: SUNE) Strengthens Financial Position Via Recently Completed Financings and Debt Reduction Newsmakers
- [ April 2, 2025 ] Quoin Pharmaceuticals (NASDAQ: QNRX) Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient Newsmakers
- [ April 2, 2025 ] Innovation Beverage Group (NASDAQ: IBG) Expands U.S. Distribution of its Award-Winning Bitters Through One of the Nation’s Largest Beverage Alcohol Distributors Newsmakers
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.